Round cell liposarcoma | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

An uncommon form of cancer known as myxocytic/round sarcoma develops in the body's fat-storing cells. MRCLS typically develops on the arms and legs. These tumors have a slow rate of growth and have the potential to metastasize. Deeper in the body, liposarcoma typically develops on the thighs or abdomen. Pain, edema, and weight changes are examples of symptoms. By making up about 30% of all soft tissue cancers, myxocytic/round sarcoma is the second most frequent type of cancer of connective tissues. The onset of mucinous/round liposarcoma typically occurs between the ages of 20 and 40. very infrequently in kids under the age of ten. Liposarcoma has a wide range of subtypes, including well-differentiated, undifferentiated, round/mucous cell, and pleomorphic. Little is known about how well these subtypes respond to chemotherapy.

Description

Round cell liposarcoma is a rare form of cancer which develops in the body's cells that store fat. The arms and legs are where MRCLS typically grows. These tumors have a slow rate of growth and can metastasize to different body regions. Deeper in the body, liposarcoma typically develops on the thighs or abdomen. Pain, swelling, and weight changes are examples of symptoms. It can spread throughout the body if left untreated. Approximately 30% of all soft tissue cancers are caused by it, making it the second most prevalent soft tissue cancer. Mucinous/round liposarcoma typically develops between 20 and 40 years of age. very infrequently in kids under the age of ten. Although there is no known cause, a history of trauma or prior trauma increases the likelihood that a tumor will continue to grow in the affected area. Of all liposarcomas, pure myeloid LPS (MLPS) makes up 30%. Round cell LPS (RCLPS) is a subtype of MLPS that makes up 15% of all LPS and is associated with a round cell component in 5% of tumors. Both MLPS and RCLPS had the same t (12;16) (q13; p11) chromosomal translocation, which led to the transcription of the cancerous t (12;16) LPS (FUS-CHOP) transcript. Histologically, MRCLS exhibits a range of sequential lesions that exhibit striking similarities to foetal fat development and abundant differentiation from adipocytes, whereas at the other end of the range, it exhibits features of poorly differentiated round cells that are, at best, only loosely differentiated. The shared clinical characteristics and frequent chromosomal t (12; 16) translocation leading to the fusion of the TLS (FUS) and CHOP (DDT3) genes seen in the majority of these tumors suggest that MRCLS is a distinct liposarcoma family.

Round cell liposarcoma (Epidemiology)

By making up about 30% of all soft tissue cancers, myxocytic/round sarcoma is the second most frequent type of cancer of connective tissues. Mucinous/round liposarcoma typically develops between 20 and 40 years of age. extremely infrequently in kids under the age of ten. Less than 20% of all soft tissue tumors in the United States are liposarcomas, on average. Although case reports have been documented as early as infancy, the average age at diagnosis was 50. The most prevalent kind of soft tissue sarcoma worldwide, according to the American Cancer Society, is liposarcoma. There are no known risk factors for the occurrence of liposarcoma. Race and gender had no real relationships. According to some studies, men predominate slightly. Large, recently released studies showed LPS survival rates of 58-95% after approximately. Depending on the grade of the tumor, 5 years. Different LPS subtypes have various normal ages and postoperative results. Liposarcoma is the most frequent soft tissue sarcoma, with a yearly incidence of 2.5 cases per million people. It accounts for about 3% of all liposarcomas in the head and neck region (typically in the neck and cheeks), and about 17% of all soft tissue tumors. Oral intervention is uncommon. Tumors can grow on the lower extremities and trunk. 50 years of age was the average age of the patients. Although liposarcoma makes up only 4% of childhood soft tissue sarcomas, it makes up about 17% of all soft tissue tumors. Young adults and adolescents have been reported to have liposarcoma cases, but children rarely develop the disease.

Round cell liposarcoma-Current Market Size & Forecast Trends

The market for myxoid round cell liposarcoma (MRCLS) is anticipated to grow at a compound annual growth rate (CAGR) of 6.25% from 2021 to 2028. As of 2023, the MRCLS drug market is expected to gain traction due to an increase in the number of cases and a rising demand for novel treatment options. The market is driven by advancements in therapies, including chemotherapy and targeted treatments, as well as increased financial support for research and development. However, challenges such as the limited availability of specific treatments and stringent regulatory approvals may hinder growth. Overall, the MRCLS market is projected to expand significantly through 2035 as new therapies are developed and patient outcomes improve.

The response of chemotherapy for the many different subtypes of liposarcoma (such as well-differentiated, undifferentiated, round/mucous cell, and pleomorphic) is not well known. Therefore, chemotherapy response rates and overall progression-free survival were examined in various histological subtypes. Histological grade was another way to measure survival. When compared to other liposarcoma subgroups, particularly undifferentiated and well-differentiated tumors, myxoid liposarcoma has a relative chemosensitivity, according to this retrospective analysis. The classification does not offer any additional insight into how other histologic subtypes will respond to treatment in well-differentiated liposarcoma. A poor prognosis may be indicated by the presence of round cells in myxoid/round cell liposarcoma. Additionally poor prognostic indicators for myeloid/round cell tumors included the location of the tumor, the high proliferative fraction seen with MIB-1 markers, and TP53 missense mutations. Particularly in the case of the mucosal variant, radiotherapy for liposarcoma can be a significant adjunct to surgery. Chemotherapy for liposarcoma is still in the experimental stage. High-grade large liposarcoma patients may benefit from multimodality treatment with chemotherapy and radiation, despite the fact that surgical resection is still the mainstay of curative therapy. In November 2015, the US Food and Drug Administration (FDA) approved the drug trabectedin (Yondelis) for the treatment of patients with unresectable metastatic liposarcoma or leiomyosarcoma who had previously received anthracyclines. It is an alkylating substance that attaches to guanine residues in DNA's minor groove. The phase 3 study (n = 518) that served as the foundation for the approval demonstrated a statistically significant increase in progression-free survival when compared to dacarbazine (4.2 months vs. 1.5 months, P and lt, and 0.0001). There was no increase in overall survival. The microtubule inhibitor eribulin (Halaven) was authorized in the US in January 2016. FDA for the treatment of patients with anthracycline-containing metastatic or unresectable liposarcoma who have already received treatment. Based on outcomes in a subset of 143 liposarcoma patients, the US Food and Drug Administration (FDA) approved the drug. The dacarbazine group had a better survival rate at 7 months (15.6 months in the eribulin group versus 8.4 months in the dacarbazine group), according to the results of this subgroup. A secondary endpoint measured median progression-free survival, which was 2.9 months for the eribulin group and 1.7 months for the dacarbazine group. Eribulin, however, is more toxic than dacarbazine. When eribulin therapy was used versus dacarbazine, the following adverse events were more common: neutropenia (44% vs. 24%), pyrexia (28% vs. 14%), peripheral sensory neuropathy (20% vs. 4%), and hair loss (35% vs. 3%).

Report Highlights

Round cell liposarcoma- Current Market Trends

Round cell liposarcoma- Current & Forecasted Cases across the G8 Countries

Round cell liposarcoma- Market Opportunities and Sales Potential for Agents

Round cell liposarcoma- Patient-based Market Forecast to 2035

Round cell liposarcoma- Untapped Business Opportunities

Round cell liposarcoma- Product Positioning Vis-a-vis Competitors' Products

Round cell liposarcoma- KOLs Insight